They are moving toward more innovative treatments....like cell and gene therapies...
Lucky your article you posted was from over 3 years ago because that is not the direction they were taking back then in 2018 .... they appear to have flip flopped on this one thankfully and is perhaps why they have been advertising so many new roles lately ?
https://hotcopper.com.au/threads/novartis-countdown.6108431/?post_id=53825567#.YMbAZvkzbIU
And Novartis itself is known for a restless search for cost cuts wherever it can find them — which triggered their decision to scrap a special gene and cell therapy unit and integrate the group in the main development organization.
Novartis countdown, page-7
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.07 | $3.156M | 2.910M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 111598 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 100993 | 17 |
View Market Depth
| Last trade - 14.42pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.10 | $1.07 | 566509 | ||
| Last updated 15.03pm 21/05/2024 ? | |||||
| MSB (ASX) Chart |